SCHEMBL19219277

SCHEMBL19219277

Cc1cc(OCc2cn(-c3ccc(Cl)cc3)nn2)nnc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 10/20 0.58
GRIN1 Q05586 10/20 0.58
GRIN2B Q13224 10/20 0.58
P2RX7 Q99572 1/20 0.57
NPC1 O15118 2/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
CYP1A2 P05177 3/20 0.51
CYP2C19 P33261 3/20 0.51
CYP2C9 P11712 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
KMT2A Q03164 1/20 0.51
HPGD P15428 1/20 0.51
NOTUM Q6P988 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19219271 0.83 RXRA (0.66) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19219279 0.82 RXRA (0.64) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19211501 0.81 GRIN1 (0.74) RXRAGRIN1GRIN2BKCNH2
SCHEMBL19219274 0.81 RXRA (0.62) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19219272 0.78 RXRA (0.68) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19219284 0.78 RXRA (0.58) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19219276 0.77 RXRA (0.60) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19219275 0.76 RXRA (0.66) RXRAGRIN1GRIN2BP2RX7NPC1
SCHEMBL19211374 0.76 RXRA (0.82) RXRAGRIN1GRIN2B
SCHEMBL19219278 0.75 GRIN1 (0.63) RXRAGRIN1GRIN2BP2RX7NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170226089-A1 SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226089-A1 SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS GRIN3A, GRIN3B, GRIN1 RXRA 2100/4885GRIN1 3/4885GRIN2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.